Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicole Chase

Allergy & Immunology Saint Paul, MN Medical Doctor

NPI 1568646057 CMS profile 70913

565 Snelling Ave S, Saint Paul, MN 55116

Open in the dashboard

General payments

$1,800,542

1,843 records reported · program years 2019–2025

Research payments

$6,828

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,925 paid to institutions, not to them · program year 2024

Through program year 2025, Nicole Chase of Saint Paul, MN is reported in the CMS Open Payments database as having received $1,800,542 across 1,843 general payments and $6,828 in research payments paid to them. Separately, studies naming them as principal investigator received $2,925 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $416,794 390
2024 General $442,659 418
2024 Research $841 1
2023 General $425,521 441
2023 Research $5,987 2
2022 General $375,268 388
2021 General $109,383 140
2020 General $14,116 34
2019 General $16,800 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Chase
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Nicole Chase were reported at $416,794. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Nicole Chase Allergy & Immunology median Middle half National median
2019 $16,800 $594 $163–$1,512 $163
2020 $14,116 $426 $106–$1,233 $114
2021 $109,383 $638 $157–$1,708 $132
2022 $375,268 $790 $205–$1,961 $149
2023 $425,521 $852 $220–$2,147 $160
2024 $442,659 $865 $203–$2,267 $164
2025 $416,794 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $550,740 454 payments
  2. Regeneron Healthcare Solutions, Inc. $495,847 497 payments
  3. AstraZeneca Pharmaceuticals LP $494,823 509 payments
  4. Incyte Corporation $71,083 101 payments
  5. Genentech USA, Inc. $45,461 58 payments
  6. Novartis Pharmaceuticals Corporation $28,229 18 payments
  7. GlaxoSmithKline, LLC. $24,371 32 payments
  8. Blueprint Medicines Corporation $22,166 25 payments
  9. Lilly USA, LLC $21,217 15 payments
  10. Amgen Inc. $14,235 25 payments
  11. Other $32,368 109 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,252,020 441 payments
  2. Travel and Lodging $260,679 682 payments
  3. Consulting Fee $238,356 135 payments
  4. Food and Beverage $29,667 575 payments
  5. Honoraria $19,306 8 payments
  6. Grant $495 1 payment
  7. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $553,253 463 payments
  2. DUPIXENT Inflammation And Immunology $364,305 386 payments
  3. FASENRA $211,196 209 payments
  4. TEZSPIRE $115,000 112 payments
  5. AIRSUPRA $109,361 122 payments
  6. DUPIXENT Immunology And Inflammation $102,457 93 payments
  7. OPZELURA $69,043 100 payments
  8. Xolair $53,445 66 payments
  9. EBGLYSS $20,522 14 payments
  10. TRELEGY ELLIPTA $19,016 16 payments
  11. Other $72,991 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $6,828 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

850

Median for Allergy/ Immunology: 449

Drug cost

$583,287

Median for Allergy/ Immunology: $169,700

Branded share of claims

55.6%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 79 $251,414
Dupixent Syringe Dupilumab Brand 17 $95,341
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 56 $67,968
Dupixent Pen Dupilumab Brand 13 $48,131
Xhance Fluticasone Propionate Brand 24 $24,997
Breo Ellipta Fluticasone/Vilanterol Brand 30 $16,229
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 40 $14,510
Spiriva Respimat Tiotropium Bromide Brand 18 $13,804
Symbicort Budesonide/Formoterol Fumarate Brand 37 $10,551
Fluticasone Propionate Hfa Fluticasone Propionate Brand 15 $10,139

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$34,102

Medicare's payments for the services billed

Medicare patients

98

Average age 71

Services billed

1,854

68 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 42%
Osteoporosis 22%
Ischemic heart disease 18%
Depression 16%
Chronic kidney disease 14%
Cancer 14%
Diabetes 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$242,710 30 —
AIRSUPRA
$38,683 — —
OPZELURA
$37,762 — —
TEZSPIRE
$35,262 — —
FASENRA
$31,039 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

1,846 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record